Federated Hermes Inc. lowered its position in AVANOS MEDICAL, INC. (NYSE:AVNS - Free Report) by 72.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 23,364 shares of the company's stock after selling 60,402 shares during the quarter. Federated Hermes Inc. owned 0.05% of AVANOS MEDICAL worth $335,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. increased its position in AVANOS MEDICAL by 27.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,011,312 shares of the company's stock valued at $47,941,000 after purchasing an additional 644,267 shares during the period. Pacer Advisors Inc. acquired a new stake in shares of AVANOS MEDICAL during the 1st quarter worth approximately $6,056,000. Brown Advisory Inc. grew its position in shares of AVANOS MEDICAL by 12.0% during the 4th quarter. Brown Advisory Inc. now owns 1,905,094 shares of the company's stock worth $30,329,000 after buying an additional 204,218 shares during the period. Diamond Hill Capital Management Inc. acquired a new stake in shares of AVANOS MEDICAL during the 1st quarter worth approximately $2,800,000. Finally, D. E. Shaw & Co. Inc. grew its position in shares of AVANOS MEDICAL by 43.1% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 494,627 shares of the company's stock worth $7,874,000 after buying an additional 148,902 shares during the period. Institutional investors and hedge funds own 95.17% of the company's stock.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen cut AVANOS MEDICAL from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 9th.
View Our Latest Analysis on AVNS
AVANOS MEDICAL Stock Performance
Shares of AVANOS MEDICAL stock traded up $0.19 during trading hours on Thursday, hitting $10.94. 495,729 shares of the company's stock traded hands, compared to its average volume of 535,523. AVANOS MEDICAL, INC. has a 12-month low of $9.30 and a 12-month high of $25.36. The stock has a market capitalization of $507.80 million, a price-to-earnings ratio of -1.09 and a beta of 1.12. The company has a fifty day simple moving average of $11.82 and a 200-day simple moving average of $13.31. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.64 and a quick ratio of 1.58.
AVANOS MEDICAL (NYSE:AVNS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The firm had revenue of $175.00 million during the quarter, compared to the consensus estimate of $165.50 million. AVANOS MEDICAL had a negative net margin of 66.89% and a positive return on equity of 6.16%. During the same quarter in the prior year, the firm posted $0.34 earnings per share. Equities research analysts anticipate that AVANOS MEDICAL, INC. will post 1.32 EPS for the current fiscal year.
AVANOS MEDICAL Profile
(
Free Report)
Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
Further Reading

Before you consider AVANOS MEDICAL, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AVANOS MEDICAL wasn't on the list.
While AVANOS MEDICAL currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.